Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
Biological heterogeneity and low inherent immunogenicity are two features that greatly impact therapeutic management and outcome in colorectal cancer. Despite high local control rates, systemic tumor dissemination remains the main cause of treatment failure and stresses the need for new developments...
Main Authors: | Erta Kalanxhi, Sebastian Meltzer, Anne Hansen Ree |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/8/2193 |
Similar Items
-
Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives
by: Guanglin Cui
Published: (2022-05-01) -
Cutaneous Metastases in Ovarian Cancer
by: Isao Otsuka
Published: (2019-09-01) -
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
by: Julie Lang, et al.
Published: (2022-11-01) -
Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
by: Jie Zhong, et al.
Published: (2023-06-01) -
Immune checkpoint inhibitors in metastatic colorectal cancer therapy (a review)
by: P. P. Sorochan, et al.
Published: (2022-07-01)